A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Herpes Simplex VirusNeonatal Sepsis
Interventions
DRUG

Acyclovir

"Protocol V2 \& up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days)."

Trial Locations (3)

27713

Duke University, Durham

70112

Tulane School of Medicine, New Orleans

67214-4976

Wesely Medical Center, Wichita

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Phillip Brian Smith

OTHER

NCT00942084 - A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo) | Biotech Hunter | Biotech Hunter